Trial · NCT03409744
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Up to Week 216 | Up to 216 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Absolute Change in LDL-C Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Percent Change in Apolipoprotein B (Apo B) Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Absolute Change in Apo B Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Percent Change in Non-High-Density Lipoprotein Cholesterol (HDL-C) Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Absolute Change in Non-HDL-C Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Percent Change in Total Cholesterol (TC) Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Absolute Change in TC Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Percent Change in Triglycerides (TGs) Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
| Secondary | Absolute Change in TGs Over Time | Up to 120 weeks | The safety analysis set (SAF) included all participants who were enrolled and received at least 1 dose or part of a dose of open-label study treatment. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03409744/registered